analyzeportfolio
Nasdaq · Industrials

HEALTHEQUITY, INC. (HQY)

As-reported financials and SEC filings for HEALTHEQUITY, INC. The latest annual period is FY2026. The latest reported quarter is Q2 FY2027. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.

About HEALTHEQUITY, INC.

HealthEquity, Inc. provides technology-enabled services that help consumers manage tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits such as flexible spending accounts (FSAs) and health reimbursement arrangements (HRAs). The company serves consumers primarily through employer clients, benefits brokers, health plans, and other network partners. Its offerings include account administration, payment processing, investment advisory services, and benefits marketplace access.

Snapshot

Revenue
$1.31B
Revenue growth (YoY)
9.5%
Net income
$215.2M
Diluted EPS
$2.46
Gross margin
69.5%
Operating margin
24.6%
Net margin
16.4%
FCF margin
34.7%
ROE
10.2%
net income / fiscal-year-end equity
P/E
34.8×
trailing when available, otherwise FY EPS
Market cap
$7.97B
Long-term debt / equity
0.45×
non-current term debt only

Fundamentals are from SEC filings for FY2026, the latest annual period (ended January 31, 2026). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.

What changed at Healthequity

  • Revenue grew 9.5% to $1.3B in FY2026, slower than the 20.0% the year before.
  • Operating margin turned positive at 24.6% in FY2026, from a 3.2% operating loss in FY2022.
  • Most recent quarter Q2 FY2027: revenue $351M, up 7.6% from Q2 FY2026.
  • Free cash flow was $455M in FY2026, 34.7% of revenue.
  • Net income rose 122.5% to $215M in FY2026.

Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.

Peer comparison

Where Healthequity’s fundamentals sit among the 684 Industrials companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).

Gross margin69.5%
95th percentile of 466
Operating margin24.6%
93rd percentile of 605
Net margin16.4%
89th percentile of 645
FCF margin34.7%
98th percentile of 562
Revenue growth (YoY)+9.5%
65th percentile of 668
ROE10.2%
60th percentile of 600
P/E34.8×
73rd percentile of 434
Long-term debt / equity0.45×
47th percentile of 409
Short interest6.50d
86th percentile of 676

Healthequity’s FCF margin of 34.7% ranks in the 98th percentile of the 562 Industrials companies reporting it. Healthequity’s gross margin of 69.5% ranks in the 95th percentile of the 466 Industrials companies reporting it. Healthequity’s operating margin of 24.6% ranks in the 93rd percentile of the 605 Industrials companies reporting it.

No reported insider purchases (code P) in the last 90 days; 4 insider sales totaling $1.3M. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →

Percentiles describe where a figure sits among sector peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.

Institutional ownership

Held by 1 of the superinvestors we track (plus 4 quant / multi-strat books), based on each investor’s most recent 13F; periods vary by investor (newest: Q2 2026).

Conviction investors
1
+4 quant / multi-strat
Initiated / added
3
1 new, 2 added
Reduced / exited
2
2 trimmed, 0 exited
Combined position
$264.2M
reported long value
InvestorAs ofPosition valueSharesChange
AQR Capital ManagementquantQ2 2026$176.1M2.0MReduced
Citadel AdvisorsquantQ2 2026$61.7M683.0KAdded
Millennium ManagementquantQ2 2026$22.6M250.0KReduced
Gotham Asset ManagementQ2 2026$2.0M22.5KAdded
D. E. ShawquantQ2 2026$1.8M20.4KNew

From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.

Recent insider activity

Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.

Buys (90d)
0
code P
Bought (90d)
code P value
Sells (90d)
4
$1.3M
Reported activity
Net selling
by $ value, 90d
Trade dateInsiderTypeSharesPriceValue
2026-08-25
filed 2026-08-27
DILLON ADRIAN TDirectorSell6.3K$104.47$658K
2026-08-25
filed 2026-08-27
DILLON ADRIAN TDirectorSell1.3K$105.26$140K
2026-07-10
filed 2026-07-14
Fiore Michael HenryEVP, CHIEF COMMERCIAL OFFICERSell2.4K$95.00$224K
2026-07-02
filed 2026-07-07
Fiore Michael HenryEVP, CHIEF COMMERCIAL OFFICERSell2.5K$95.00$235K
2026-05-29
filed 2026-06-02
Fiore Michael HenryEVP, CHIEF COMMERCIAL OFFICERSell3.1K$95.00$298K
2026-05-28
filed 2026-06-01
Ladd DelanoEVP, General CounselSell7.5K$90.00$675K
2026-05-28
filed 2026-06-01
Wellborn Gayle FurgursonDirectorSell2.4K$90.00$220K

Reported non-derivative purchases and sales (codes P/S) — which may be open-market or private; excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.

Short interest

Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.

Shares short
4.1M
settled 2026-08-14
Change vs prior
-1.2%
vs previous settlement
Days to cover
6.50
at avg daily volume
Avg daily volume
633.8K
FINRA reported
SettlementShares shortChangeDays to cover
2026-08-144.1M-1.2%6.50
2026-07-314.2M-17.3%5.93
2026-07-155.0M-4.4%6.01
2026-06-305.3M+14.3%4.46
2026-06-154.6M+11.6%5.16
2026-05-294.1M-8.3%3.47
2026-05-154.5M-11.0%5.64
2026-04-305.1M+22.9%5.45

Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.

Income statement (as reported)

 FY2026FY2025FY2024FY2023FY2022
Revenue$1.31B$1.20B$999.6M$861.7M$756.6M
Gross profit$913.1M$777.3M$622.6M$491.9M$424.8M
Operating income$322.5M$162.3M$117.7M$9.1M$-24.2M
Net income$215.2M$96.7M$55.7M$-26.1M$-44.3M
Diluted EPS$2.46$1.09$0.64$-0.31$-0.53

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Balance sheet (as reported)

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Cash flow (as reported)

 FY2026FY2025FY2024FY2023FY2022
Operating cash flow$457.1M$339.9M$242.8M$150.7M$141.0M
Capital expenditure$2.0M$2.1M$1.7M$3.4M$8.9M
Free cash flow$455.1M$337.8M$241.1M$147.3M$132.1M

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Quarterly trend (as reported)

QuarterRevenueRevenue YoYNet incomeDiluted EPS
Q2 FY2027$350.7M7.6%$65.6M$0.78
Q1 FY2027$354.6M7.2%$69.4M$0.82
Q4 FY2026$334.6M7.3%$49.7M$0.57
Q3 FY2026$322.2M7.2%$51.7M$0.59
Q2 FY2026$325.8M8.6%$59.9M$0.68
Q1 FY2026$330.8M15.0%$53.9M$0.61
Q4 FY2025$311.8M18.8%$26.4M$0.30
Q3 FY2025$300.4M20.5%$5.7M$0.06

Latest 8 reported quarters, from company XBRL filings on SEC EDGAR.

Company facts

ExchangeNasdaq
SectorIndustrials
SIC industryServices-Business Services, NEC
Latest annual periodFY2026 (ended January 31, 2026)
Latest reported quarterQ2 FY2027 (ended July 31, 2026)
Oldest indexed filing2016
SEC CIK1428336

Selected SEC filings

10-Q2026-08-27
View on EDGAR →
10-Q2026-05-28
View on EDGAR →
8-K2026-08-27
View on EDGAR →
8-K2026-06-26
View on EDGAR →
8-K2026-05-28
View on EDGAR →
8-K2026-05-08
View on EDGAR →

Largest Industrials peers

All Industrials companies →

Monitor HQY

Get an alert when Healthequity files something material, see which superinvestors own it, and ask its filings a question with cited answers.

Monitor HQY free

Includes one free filing-grounded research answer. Or check your whole portfolio, no account needed.

Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.